<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04880044</url>
  </required_header>
  <id_info>
    <org_study_id>CASE1221</org_study_id>
    <nct_id>NCT04880044</nct_id>
  </id_info>
  <brief_title>Detection of Barrett s Esophagus in Patients Without GERD Symptoms</brief_title>
  <official_title>Detection of Barrett s Esophagus in Patients Without Gastroesophageal Reflux Disease (GERD) Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to develop a method to detect Barrett's esophagus (BE) in&#xD;
      individuals with a new office-based diagnostic test.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will investigate whether using EsoCheck/EsoGuard(EC/EG) can detect BE in&#xD;
      individuals at risk for BE who are currently not being detected and are not undergoing&#xD;
      routine esophago-gastro-duodenoscopy (EGD)&#xD;
&#xD;
      BE can only be diagnosed by performing upper endoscopy. Up to 500 adults who have risk&#xD;
      factors for BE but do not have chronic heartburn or regurgitation will be enrolled in this&#xD;
      study. This will include the EsoCheck/EsoGuard determination along with the upper endoscopy&#xD;
      for qualifying EsoGuard negative subjects&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positive predictive value (PPV) of EC/EG in a non-GERD population that has three or more non-GERD risk factors for BE.</measure>
    <time_frame>Up to 2 months</time_frame>
    <description>PPV of EC/EG in a non-GERD population that has three or more non-GERD risk factors for BE. Participants who are at risk will be offered EC/EG. Those who are positive will undergo subsequent EGD&#xD;
PPV = (EC/EG positive &amp; EGD positive) / ((EC/EG positive &amp; EGD positive) + (EC/EG positive &amp; EGD negative))</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants negative via EC/EG who subsequently are proven negative via EGD</measure>
    <time_frame>Up to 2 months</time_frame>
    <description>Negative Predictive Value (NPV):&#xD;
Proportion of participants negative via EC/EG who subsequently are proven negative via EGD. This will be measured by offering EGD to a proportion of patients who are EC/EG negative.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Barrett's Esophagus</condition>
  <arm_group>
    <arm_group_label>EC/EG &amp; EGD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will complete a study questionnaire about reflux symptoms. Performance of an EsoCheck (EC) procedure; the EC sample will subsequently be tested with the EsoGuard (EG) assay&#xD;
If EG assay results come back positive, participant is requested to complete standard of care (SOC) upper endoscopy (tissue samples collected)&#xD;
If EG assay results come back negative, selected participants (100 volunteers) will also undergo a research EGD if they consent</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>EsoCheck/EsoGuard (EC/EG)</intervention_name>
    <description>EC is a swallowed capsule on a tethered catheter that obtains a touch sample of the distal esophagus. The obtained sample is placed in a buffer and sent to a diagnostics lab for testing of methylated markers from extracted DNA. EG is a methylated DNA test . A positive EG is associated with Barrett's esophagus at all its stages.</description>
    <arm_group_label>EC/EG &amp; EGD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Esophago-gastro-duodenoscopy (EGD)</intervention_name>
    <description>SOC diagnostic endoscopic procedure that visualizes the upper part of the gastrointestinal tract down to the duodenum. Tissue samples collected.</description>
    <arm_group_label>EC/EG &amp; EGD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  No known coagulopathy, no known esophageal varices.&#xD;
&#xD;
          -  No significant dysphagia or odynophagia&#xD;
&#xD;
          -  Absence of chronic GERD, defined as five or more years of heartburn or regurgitation&#xD;
             with symptoms at least once a week when not on medications for GERD symptoms.&#xD;
&#xD;
          -  Subjects to qualify must meet criterion 3, be over age 50, and have two additional&#xD;
             risk factors for BE (white race, central obesity defined as waist size &gt;35 inches for&#xD;
             women and &gt;40 inches for men, male gender, current smoker or smoking history &gt;10 pack&#xD;
             years, confirmed family history in at least two members with one being a first degree&#xD;
             relative).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of prior EGD procedure&#xD;
&#xD;
          -  Inability to provide written informed consent&#xD;
&#xD;
          -  History of weekly of more frequent heartburn or regurgitation for five or more years&#xD;
&#xD;
          -  On anti-coagulant drug(s)that cannot be temporarily discontinued or coagulopathy with&#xD;
             international normalized ratio (INR) &gt; 1.5&#xD;
&#xD;
          -  Known history of esophageal varices or esophageal stricture&#xD;
&#xD;
          -  Any contraindication, as deemed inInvestigator's medical judgment, to undergoing the&#xD;
             EsoCheck procedure, undergoing the EGDprocedure,and/or having biopsies taken,&#xD;
             including but not limited to due to comorbidities such as coagulopathy or a known&#xD;
             history of esophageal diverticula, esophageal fistula and/or esophageal ulceration&#xD;
&#xD;
          -  History of difficulty swallowing (dysphagia) or painful swallowing (odynophagia),&#xD;
             including swallowing pills&#xD;
&#xD;
          -  Oropharyngeal tumor&#xD;
&#xD;
          -  History of esophageal or gastric surgery, with exception on uncomplicated surgical&#xD;
             fundoplication procedure&#xD;
&#xD;
          -  History of myocardial infarction or cerebrovascular accident within past 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amitabh Chak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amitabh Chak, MD</last_name>
    <phone>1-800-641-2422</phone>
    <email>CTUReferral@UHhospitals.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Amitabh Chak, MD</last_name>
      <phone>800-641-2422</phone>
      <email>CTUReferral@UHhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Amitabh Chak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 5, 2021</study_first_submitted>
  <study_first_submitted_qc>May 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Barrett Esophagus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All individual participant data (IPD) that result in publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

